Market Overview

The Global Antibody-drug Conjugates Market was valued at USD 12,145.3 million in 2023 and is expected to reach USD 96,660.6 million by 2031 while growing at a CAGR of 29.6% during the forecast period (2024-2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Market Dynamics

This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global antibody-drug conjugates market growth. Antibody-drug conjugates (ADCs) merge monoclonal antibodies' specificity with chemotherapy drugs' cytotoxic potential for targeted cancer therapy. This method seeks to selectively deliver chemotherapy to cancer cells, minimizing harm to nearby healthy tissues. ADCs typically include a monoclonal antibody, a linker, and a cytotoxic payload in their structure.

Advances in Biotechnology, Immunology, and ongoing drug delivery research are anticipated to fuel antibody-drug conjugates market growth. However, obstacles like ongoing drug delivery research and stringent regulatory requirements may impede market expansion.

Furthermore, the global antibody-drug conjugates industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.

Segmentation – By Product Type Analysis

The Global Antibody-Drug Conjugates Market is segmented among Adcetris, Kadcyla, and Other Product Types, based on product type. In 2023, Kadcyla accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Segmentation – By Application Analysis

The Global Antibody-Drug Conjugates Market is segmented among Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Other Applications, based on Application. In 2023, Breast Cancer accounted for the majority of the market share*. 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Global Antibody-drug Conjugates Market: Regional Analysis

Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031). 

 *Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report

Competitive Landscape

Some of the key players operating in the market are Seagen Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, AbbVie Inc., Takeda Pharmaceutical Company Ltd, and AstraZeneca PLC.

Table of Contents:

1. Research Methodology and Market Scope

• Research Methodology

• Market Scope

2. Executive Summary

3. Global Antibody-drug Conjugates Market Dynamics

• Drivers

• Restraints

• Opportunity

4. Global Antibody-drug Conjugates Industry Analysis

• PEST Analysis

• Porter's Five Force Analysis

• Recent Deals Analysis

5. Global Antibody-drug Conjugates Market Segmentation, By Product Type

• Global Antibody-drug Conjugates Market Share Analysis, By Product Type

• Global Antibody-drug Conjugates Market Growth Analysis, By Product Type

• Global Antibody-drug Conjugates Market Trends, By Product Type

o Adcetris

o Kadcyla

o Other Product Types

6. Global Antibody-drug Conjugates Market Segmentation, By Application

• Global Antibody-drug Conjugates Market Share Analysis, By Application

• Global Antibody-drug Conjugates Market Growth Analysis, By Application

• Global Antibody-drug Conjugates Market Trends, By Application

o Blood Cancer

o Breast Cancer

o Ovary Cancer

o Lung Cancer

o Skin Cancer

o Brain Tumor

o Other Application

7. Global Antibody-drug Conjugates Market Segmentation, By Technology

• Global Antibody-drug Conjugates Market Share Analysis, By Technology

• Global Antibody-drug Conjugates Market Growth Analysis, By Technology

• Global Antibody-drug Conjugates Market Trends, By Technology

o Cleavable Linker

o Non-cleavable Linker

8. Global Antibody-drug Conjugates Market Segmentation, By Target Type

• Global Antibody-drug Conjugates Market Share Analysis, By Target Type

• Global Antibody-drug Conjugates Market Growth Analysis, By Target Type

• Global Antibody-drug Conjugates Market Trends, By Target Type

o CD30 Antibodies

o HER2 Antibodies

o Other Target Types

9. Global Antibody-drug Conjugates Market Segmentation, By End User

• Global Antibody-drug Conjugates Market Share Analysis, By End User

• Global Antibody-drug Conjugates Market Growth Analysis, By End User

• Global Antibody-drug Conjugates Market Trends, By End User

o Hospitals and Speciality Cancer Centers

o Biotechnology and Pharmaceutical Companies

o Other End Users

10. Global Antibody-drug Conjugates Market Segmentation, By Region

• Global Antibody-drug Conjugates Market Share Analysis, By Region

• Global Antibody-drug Conjugates Market Growth Analysis, By Region

• Global Antibody-drug Conjugates Market Trends, By Region

o North America

o Europe

o Asia Pacific

o Latin America

o Middle East

o Africa

11. Competitive Landscape

• Seagen Inc. *

o Company Overview

o Financial Performance

o Key Development/Strategies

o SWOT Analysis

• ImmunoGen Inc.

• Mersana Therapeutics Inc.

• Pfizer Inc.

• F. Hoffmann-La Roche Ltd

• Sorrento Therapeutics Inc.

• Oxford BioTherapeutics Ltd

• AbbVie Inc.

• Takeda Pharmaceutical Company Ltd

• AstraZeneca PLC

 *Similar analysis will be provided for each company listed above.